Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,783,496
  • Shares Outstanding, K 86,915
  • Annual Sales, $ 23,680 K
  • Annual Income, $ -318,760 K
  • EBIT $ -306 M
  • EBITDA $ -320 M
  • 60-Month Beta 0.48
  • Price/Sales 15.95
  • Price/Cash Flow N/A
  • Price/Book 15.43

Options Overview Details

View History
  • Implied Volatility 129.25% (+0.56%)
  • Historical Volatility 44.60%
  • IV Percentile 98%
  • IV Rank 80.52%
  • IV High 150.01% on 10/16/25
  • IV Low 43.42% on 01/21/25
  • Expected Move (DTE 33) 2.92 (14.21%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 4,202
  • Volume Avg (30-Day) 1,066
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 30,766
  • Open Int (30-Day) 29,900
  • Expected Range 17.60 to 23.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 6
  • High Estimate -0.46
  • Low Estimate -0.90
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.57 +4.85%
on 01/13/26
22.73 -9.72%
on 12/23/25
-0.20 (-0.97%)
since 12/16/25
3-Month
12.99 +57.97%
on 10/27/25
22.73 -9.72%
on 12/23/25
+5.47 (+36.35%)
since 10/16/25
52-Week
8.58 +139.16%
on 05/15/25
22.73 -9.72%
on 12/23/25
+7.52 (+57.85%)
since 01/16/25

Most Recent Stories

More News
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand...

SNDX : 20.52 (-0.73%)
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast...

SNDX : 20.52 (-0.73%)
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 20.52 (-0.73%)
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ®...

SNDX : 20.52 (-0.73%)
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute...

SNDX : 20.52 (-0.73%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December...

SNDX : 20.52 (-0.73%)
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 20.52 (-0.73%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November...

SNDX : 20.52 (-0.73%)
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 20.52 (-0.73%)
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

– $45.9 million in total revenue, representing 21% growth over 2Q25 –  – $32.0 million Revuforj ® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25,...

SNDX : 20.52 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 21.97
2nd Resistance Point 21.58
1st Resistance Point 21.05
Last Price 20.52
1st Support Level 20.13
2nd Support Level 19.74
3rd Support Level 19.21

See More

52-Week High 22.73
Last Price 20.52
Fibonacci 61.8% 17.32
Fibonacci 50% 15.65
Fibonacci 38.2% 13.99
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar